Novozymes A/S – ADR ( (NVZMY) ) has released its Q1 earnings. Here is a breakdown of the information Novozymes A/S – ADR presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Novozymes A/S, part of the Novonesis Group, is a global biotechnology company specializing in enzyme production, serving industries such as food and beverages, household care, and agriculture. In the first quarter of 2025, Novozymes reported strong financial performance, with a notable 11% organic sales growth and a 27% increase in adjusted net profit. This growth was driven by innovation and strong demand across both emerging and developed markets. Key financial highlights include an adjusted EBITDA margin of 38.3% and a net interest-bearing debt to EBITDA ratio of 1.1x. The company also announced a strategic acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance, expected to close in the second quarter, which aligns with its growth strategy. Looking ahead, Novozymes maintains its full-year outlook of 5-8% organic sales growth and an adjusted EBITDA margin between 37-38%, despite currency headwinds. The company remains confident in its resilient global setup and ability to meet solid demand across its business segments.